Limited data suggest antidepressants, topical capsaicin, and fat grafting may reduce pain associated with post-mastectomy pain syndrome.
An immediate 1-stage IBBR with use of ADMs after mastectomy may carry a higher risk for complications compared to 2-stage IBBR.
Fear of cancer recurrence seems to be a primary reason why breast cancer patients choose to have their cancer-free breast removed.
New changes in the National Comprehensive Cancer Network Guidelines (NCCN) could indicate increasing physician comfort.
Cavity shaving halved the rates of positive margins and reexcision among patients undergoing partial mastectomy for breast cancer.
Women with early-stage breast cancer who choose to preserve the nipple during a mastectomy have similar survival or recurrence rates.
More than a third with locally-advanced breast cancer don't get radiation therapy aimed at preventing tumor's return.
Significant improvements in outcomes found despite similar patterns of relapse in breast cancer patients.
Better breast reconstruction outcomes may be one reason behind the trend of rising mastectomy rates.
Currently, one in four women with breast cancer require a follow-up surgery for conservation.
Survey of women with breast cancer explores factors in the decision to remove a healthy breast.
But the complication rate associated with breast cancer surgery and reconstruction is small.
Celebrity story helped double rates of genetic testing in following six months at one cancer center.
Factors linked to not undergoing reconstruction include black race, lower educational level, age.
Mutated versions of a gene called PALB2 can dramatically increase a woman's risk of breast cancer, a new study has found.
Survival benefit between women who've had a preventive mastectomy and those who kept their healthy breast was less than 1%.
Majority of BRCA mutation carriers opted for different surgery than initially planned by their surgeons.
Receipt of CPM linked to genetic testing, family history, MRI receipt, and worry about recurrence.
Speed of testing will provide information that can alter treatment decisions.
ASCO updates its 2005 guideline for use of sentinel node biopsy in early breast cancer.
For women with a BRCA mutation, delaying oophorectomy beyond age 35 sharply increases the risk of cancer and mortality.
Reductions seen in locoregional recurrence, overall recurrence, breast cancer mortality.
The use of breast reconstruction in breast cancer patients undergoing mastectomy has been increasing in the United States.
Women with BRCA mutations and early-stage breast cancer who underwent bilateral mastectomy vs. unilateral mastectomy are less likely to die from the disease.
Recent studies have revealed disappointing results for gemcitabine—but more support for taxane-first sequencing.
Most women breast cancer treated with breast-conserving surgery or mastectomy with axillary surgery experience postoperative pain.
Women with metastatic breast cancer who respond to chemotherapy should not receive locoregional treatment.
Invasive DFS was 92% after adjuvant trastuzumab plus docetaxel/carboplatin in patients with HER-2 positive breast cancer.
Males are less likely to receive breast conservation therapy for treatment of breast cancer.
Travel distance to a comprehensive cancer center is associated with stage of breast cancer at diagnosis and surgery type.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Despite Promising Trial Results, Skeptics Raise Red Flags About Anlotinib's Efficacy in Heavily Treated NSCLC
- Higher Risk of MGUS in Relatives of Patients With Multiple Myeloma Confirmed
- Brentuximab Vedotin Combo Active in Older Patients With Hodgkin Lymphoma
- Prostate Cancer Drug Resistance Mediated by Epigenetic Changes
- Nilotinib and Dasatinib Confer Similar Outcomes for Chronic-Phase CML